IRIDEX (IRIX) - 2023 Q4 - Earnings Call Transcript

We expect sales to stabilize throughout the year as orders are backfilled and the resumption of regular purchasing behavior from the glaucoma practices. Our retina segment revenue in Q4 was $7.5 million, a decrease of 7% compared to the prior year period. In the quarter, we continue to see elongated capital purchase cycles and distributor destocking. For the full year '23, retina product revenue was $29.4 million, down 7% compared to 2022. As customer capital purchase plans remain generally intact, we antic ...